These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 17944917)

  • 1. Treatment of primary advanced and recurrent endometrial carcinoma with a combination of carboplatin and paclitaxel-long-term follow-up.
    Sorbe B; Andersson H; Boman K; Rosenberg P; Kalling M
    Int J Gynecol Cancer; 2008; 18(4):803-8. PubMed ID: 17944917
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Leuven dose-dense paclitaxel/carboplatin regimen in patients with primary advanced or recurrent endometrial carcinoma.
    Vandenput I; Vergote I; Leunen K; Berteloot P; Neven P; Amant F
    Int J Gynecol Cancer; 2009 Aug; 19(6):1147-51. PubMed ID: 19820384
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A trial of outpatient paclitaxel and carboplatin for advanced, recurrent, and histologic high-risk endometrial carcinoma: preliminary report.
    Price FV; Edwards RP; Kelley JL; Kunschner AJ; Hart LA
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-78-S15-82. PubMed ID: 9346228
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Carboplatin and paclitaxel in advanced or metastatic endometrial cancer.
    Pectasides D; Xiros N; Papaxoinis G; Pectasides E; Sykiotis C; Koumarianou A; Psyrri A; Gaglia A; Kassanos D; Gouveris P; Panayiotidis J; Fountzilas G; Economopoulos T
    Gynecol Oncol; 2008 May; 109(2):250-4. PubMed ID: 18299146
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Weekly paclitaxel-carboplatin regimen in patients with primary advanced or recurrent endometrial carcinoma.
    Vandenput I; Vergote I; Neven P; Amant F
    Int J Gynecol Cancer; 2012 May; 22(4):617-22. PubMed ID: 22426408
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of the combination paclitaxel/carboplatin in patients with previously treated advanced ovarian carcinoma: a multicenter French Groupe des Investigateurs Nationaux pour l'Etude des Cancers Ovariens phase II study.
    Pujade-Lauraine E; Guastalla JP; Weber B; Curé H; Orfeuvre H; Mousseau M; Vincent P; Diéras V; Tubiana-Mathieu N; Jacquin JP; Mignot L; Leduc B; Paraïso D; Viens P
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-30-S15-35. PubMed ID: 9346219
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of advanced or recurrent endometrial carcinoma with doxorubicin in patients progressing after paclitaxel/carboplatin: Memorial Sloan-Kettering Cancer Center experience from 1995 to 2009.
    Makker V; Hensley ML; Zhou Q; Iasonos A; Aghajanian CA
    Int J Gynecol Cancer; 2013 Jun; 23(5):929-34. PubMed ID: 23598889
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Paclitaxel, Carboplatin, and Bevacizumab in Advanced and Recurrent Endometrial Carcinoma.
    Rose PG; Ali S; Moslemi-Kebria M; Simpkins F
    Int J Gynecol Cancer; 2017 Mar; 27(3):452-458. PubMed ID: 28187088
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Carboplatin plus paclitaxel in the treatment of advanced or recurrent endometrial carcinoma.
    Michener CM; Peterson G; Kulp B; Webster KD; Markman M
    J Cancer Res Clin Oncol; 2005 Sep; 131(9):581-4. PubMed ID: 15959825
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II trial of paclitaxel, carboplatin, and bevacizumab in advanced and recurrent endometrial carcinoma (EMCA).
    Simpkins F; Drake R; Escobar PF; Nutter B; Rasool N; Rose PG
    Gynecol Oncol; 2015 Feb; 136(2):240-5. PubMed ID: 25485782
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Paclitaxel and carboplatin in the treatment of advanced or recurrent endometrial cancer: a large retrospective study.
    Sovak MA; Dupont J; Hensley ML; Ishill N; Gerst S; Abu-Rustum N; Anderson S; Barakat R; Konner J; Poyner E; Sabbatini P; Spriggs DR; Aghajanian C
    Int J Gynecol Cancer; 2007; 17(1):197-203. PubMed ID: 17291253
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Taxane Plus Platinum Regimens vs Doxorubicin Plus Cisplatin as Adjuvant Chemotherapy for Endometrial Cancer at a High Risk of Progression: A Randomized Clinical Trial.
    Nomura H; Aoki D; Michimae H; Mizuno M; Nakai H; Arai M; Sasagawa M; Ushijima K; Sugiyama T; Saito M; Tokunaga H; Matoda M; Nakanishi T; Watanabe Y; Takahashi F; Saito T; Yaegashi N;
    JAMA Oncol; 2019 Jun; 5(6):833-840. PubMed ID: 30896757
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized phase II study comparing docetaxel plus cisplatin, docetaxel plus carboplatin, and paclitaxel plus carboplatin in patients with advanced or recurrent endometrial carcinoma: a Japanese Gynecologic Oncology Group study (JGOG2041).
    Nomura H; Aoki D; Takahashi F; Katsumata N; Watanabe Y; Konishi I; Jobo T; Hatae M; Hiura M; Yaegashi N
    Ann Oncol; 2011 Mar; 22(3):636-642. PubMed ID: 20696677
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Carboplatin and nonpegylated liposomal doxorubicin in primary advanced or recurrent endometrial cancer: a phase 2 trial conducted by AGO Austria.
    Volgger B; Zeimet AG; Reinthaller A; Petru E; Schauer C; Klein M; Sevelda-Schwarzgruber U; Bogner G; Wolfram G; Marth C
    Int J Gynecol Cancer; 2015 Feb; 25(2):257-62. PubMed ID: 25611899
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment with paclitaxel plus carboplatin, alone or with irradiation, of advanced or recurrent endometrial carcinoma.
    Arimoto T; Nakagawa S; Yasugi T; Yoshikawa H; Kawana K; Yano T; Taketani Y
    Gynecol Oncol; 2007 Jan; 104(1):32-5. PubMed ID: 16996113
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Paclitaxel and carboplatin with amifostine in advanced, recurrent, or refractory endometrial adenocarcinoma: a phase II study of the Southwest Oncology Group.
    Scudder SA; Liu PY; Wilczynski SP; Smith HO; Jiang C; Hallum AV; Smith GB; Hannigan EV; Markman M; Alberts DS;
    Gynecol Oncol; 2005 Mar; 96(3):610-5. PubMed ID: 15721401
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Paclitaxel and carboplatin, alone or with irradiation, in advanced or recurrent endometrial cancer: a phase II study.
    Hoskins PJ; Swenerton KD; Pike JA; Wong F; Lim P; Acquino-Parsons C; Lee N
    J Clin Oncol; 2001 Oct; 19(20):4048-53. PubMed ID: 11600606
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A feasibility study of sequential doublet chemotherapy comprising carboplatin-doxorubicin and carboplatin-paclitaxel for advanced endometrial adenocarcinoma and carcinosarcoma.
    Ang JE; Shah RN; Everard M; Keyzor C; Coombes I; Jenkins A; Thomas K; A'Hern R; Jones RL; Blake P; Gabra H; Hall G; Gore ME; Kaye SB
    Ann Oncol; 2009 Nov; 20(11):1787-93. PubMed ID: 19542250
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Concomitant paclitaxel plus carboplatin and radiotherapy for high-risk or advanced endometrial cancer.
    Wen Q; Shao Z; Yang Z
    Int J Gynecol Cancer; 2013 May; 23(4):685-9. PubMed ID: 23615571
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Weekly low-dose paclitaxel and carboplatin in the treatment of advanced or recurrent cervical and endometrial cancer.
    Secord AA; Havrilesky LJ; Carney ME; Soper JT; Clarke-Pearson DL; Rodriguez GC; Berchuck A
    Int J Clin Oncol; 2007 Feb; 12(1):31-6. PubMed ID: 17380438
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.